
Glytas M 60mg/500mg Tablet ER
Marketer
Tas Med India Pvt Ltd
Salt Composition
Gliclazide (60mg) + Metformin (500mg)
Overview Glytas M 60mg/500mg Tablet ER
Metformin/glimepiride extended-release tablets (60mg/500mg) are classified as antidiabetic medications. This dual-action formulation treats type 2 diabetes in adults by managing blood glucose levels. Administer this medication with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision loss, neuropathy, and limb amputation. Remember, this medication is part of a comprehensive diabetes management plan encompassing diet, exercise, and weight management as directed by your doctor. Lifestyle choices are vital for diabetes control. Common adverse effects include hypoglycemia (low blood sugar), characterized by sweating, dizziness, headache, and tremors; constipation; and vomiting. Maintain regular mealtimes and carry readily available glucose sources (e.g., sugary snacks, fruit juice) to counteract hypoglycemia. Alcohol consumption should be limited due to its potential to exacerbate low blood sugar. Additional possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before commencing treatment. Pregnant or lactating women should seek medical advice prior to use. Regular blood glucose monitoring is necessary, and your doctor may order blood tests to assess blood cell counts and liver function.
Uses of Glytas M 60mg/500mg Tablet ER
Adult-onset diabetes
Major Benefits of Glytas M 60mg/500mg Tablet ER:
Follow your physician's instructions precisely regarding dosage and treatment length for Glytas M 60mg/500mg Extended-Release Tablets. Ingest the tablets whole; avoid chewing, crushing, or breaking them. Administer this medication with a meal.
Common Side effects of Glytas M 60mg/500mg Tablet ER:
- Hypoglycemia (low blood glucose level)
- Headache
- Dizziness
- Diarrhea
- Upper respiratory tract infection
- Nausea
- Flatulence
- Constipation
How to use Glytas M 60mg/500mg Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Glytas M 60mg/500mg Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. Consume this medication with food.
How Glytas M 60mg/500mg Tablet ER works:
Extended-release Glytas M tablets (60mg/500mg) contain gliclazide and metformin, both agents used to manage blood sugar levels.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glytas M 60mg/500mg Extended-Release tablets with alcohol is not advisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Extended-release Glytas M 60mg/500mg tablets pose a confirmed risk to fetal development and should not be taken during pregnancy. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Glytas M 60mg/500mg tablets are likely not safe for use while breastfeeding. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Patients with kidney impairment should use Glytas M 60mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates Glytas M 60mg/500mg Extended-Release tablet use. Physician consultation is necessary. Regular kidney function monitoring is recommended during treatment.
LiverCAUTION
Patients with liver disease should use Glytas M 60mg/500mg Extended-Release tablets cautiously, as dose modification may be necessary. Individuals with severe liver impairment should avoid this medication. A lower initial dose is typically prescribed for those with mild to moderate liver disease. Physician consultation is recommended.
What if you forget to take Glytas M 60mg/500mg Tablet ER :
Should you forget to take a Glytas M 60mg/500mg Extended-Release tablet, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glytas M 60mg/500mg Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Treatment |
